Titlebook: Drug-Coated Balloons; Applications in Inte Bernardo Cortese Book 2019 Springer Nature Switzerland AG 2019 drug-eluting balloon.angioplasty

Abominate

Stent Use After Drug-Coated Balloons,though further investigations to evaluate endothelization patterns and long-term clinical outcomes are required, bailout DES implantation is a reasonable strategy to manage suboptimal DCB results, especially when treating complex lesions.

馬具

avenge

Local Drug Delivery to Prevent Restenosis of the Coronary and Peripheral Arteries,ing very short balloon-vessel contact, without the need for implantation of permanent scaffolds. The antirestenotic drug prevents restenosis after vascular intervention through inhibition of neointimal hyperplasia [3–5] and possibly by modification of the arterial remodeling response [3, 6, 7].

neuron

Design Parameters for Drug-Coated Balloons II,tory need to consider certain criteria. DCB development needs to fulfill multiple criteria with regard to the drug, device, drug carrier, physicochemical properties of the drug and drug carrier, particle size and coating methodology.

left-ventricle

,From Drug-Eluting Balloon to Drug-Coated Balloon … to Eradication of Intracoronary Metal, a New Enddisease treatment with three Palmaz-Schatz stents (not yet approved in the USA by the FDA) [1]; the second one was a recanalization of a CTO with a laser wire in a patient included in the TOTAL trial [2]; the third one was a drug-eluting balloon treatment (the Dispatch balloon) post balloon angiopla

Tartar

Previous Mistakes with DCB Technology, and How to Prevent Them in the Future,n angioplasty covered by an antiproliferative drug. This technology allows to bring high concentration of an antiproliferative drug with rapid local delivery without the implantation of an external prosthesis like a metal stent or a scaffold, technologies associated with some late-occurring thrombot

關(guān)心

violate

Technical Insights on Drug-Coated Balloons, The most striking revolution in the percutaneous treatment of coronary artery disease has undoubtedly been the introduction of the drug-eluting stent (DES). Drug-eluting stents made a revolution in interventional cardiology, not only by improving the mechanical limitations of balloon angioplasty bu

矛盾

Technical Insights on Drug-Coated Balloons II,ease of the drug to treat posttreatment shortcomings. Currently paclitaxel and sirolimus are the only choices for drug-coated balloons. Preclinical study findings on paclitaxel are mixed and depend on various factors such as the drug carrier, balloon surface, drug size, coating method etc. The sirol

周年紀(jì)念日

Design Parameters for Drug-Coated Balloons II,xel and sirolimus are two choices in DCBs and both drugs have their own advantages. Use of sirolimus on DCBs is not yet well known but may replace use of of paclitaxel in the coming years when key design criteria are compared. From the scientific perspective, researchers developing DCB in the labora